Pharmaceutical - Novo Nordisk, Asia-Pacific


Current filters:

Novo NordiskAsia-Pacific

Popular Filters

Novo Nordisk’s NovoEight passes first stage of Japanese approval

Novo Nordisk’s NovoEight passes first stage of Japanese approval


Danish insulin giant Novo Nordisk’s recombinant factor VIII product NovoEight (turoctocog alfa) has…

Asia-PacificHematologyNovo NordiskNovoEightPharmaceuticalRare diseasesRegulation

Growth drivers for China's type 2 diabetes market


The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Sanofi latest to be implicated Chinese bribery allegations


In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord


Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin


Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review


Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

Russia's Renova invests in Novelos; Novo Nordisk opens Vietnam office


USA-based Novelos Therapeutics (OTCQX: NVLT), which is developing novel drugs for the treatment and diagnosis…

Asia-PacificDiabetesFinancialMarkets & MarketingNovelos TherapeuticsNovo NordiskOncologyPharmaceutical

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016


The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

EMA panel backing for Novo Nordisk's Tresiba and Ryzodeg: Japanese review


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday announced…

Asia-PacificDegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk invests $100 million for bigger R&D center in China


Denmark's Novo Nordisk (NOV: N) said this morning that it is investing an additional $100 million to…

Asia-PacificFinancialNovo NordiskPharmaceuticalResearch

Novo Nordisk insulin degludec passes first regulatory hurdle in Japan


Danish insulin giant Novo Nordisk (NOV: N) revealed on Friday that its ultra-long-acting insulin degludec…

Asia-PacificDegludecDiabetesNovo NordiskPharmaceuticalRegulation

New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit


The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to fund…

Asia-PacificDiabetesGlucaGenNovo NordiskNovoMixNovoSevenPharmaceuticalPricingRegulation

Pfizer and Biocon cancel biosimilars deal


Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical




Back to top